A prime example of this is the use of STINGel to deliver synthetic cyclic dinucleotides (CDNs), a new class of immunotherapy drugs that has been shown to strongly induce an anti-tumor immune response by activating the Stimulator of Interferon Genes (STING) pathway [29]. This evidence concerns the gene STING1 and neoplasm.